Abstract |
An international randomized trial in Langerhans cell histiocytosis (LCH) has been initiated by the Histiocyte Society. This report reviews the rationale, design, and progress of LCH-I, which compares etoposide (VP-16) and vinblastine in the treatment of disseminated LCH. Data on the risk of etoposide-associated ( therapy-induced) malignancy, in the setting of histiocytosis, are reviewed. The available evidence leads to the recommendation that the study of etoposide in LCH should be continued.
|
Authors | S Ladisch, H Gadner, M Aricò, V Broadbent, N Grois, A Jacobson, D Komp, H S Nicholson |
Journal | Medical and pediatric oncology
(Med Pediatr Oncol)
Vol. 23
Issue 2
Pg. 107-10
( 1994)
ISSN: 0098-1532 [Print] United States |
PMID | 8202031
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Vinblastine
- Etoposide
- Methylprednisolone
|
Topics |
- Drug Administration Schedule
- Etoposide
(administration & dosage, adverse effects, therapeutic use)
- Histiocytosis, Langerhans-Cell
(drug therapy)
- Humans
- Leukemia
(chemically induced)
- Methylprednisolone
(administration & dosage)
- Vinblastine
(administration & dosage, therapeutic use)
|